Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Sanofi SNY announced that the European Medicines Agency (EMA) has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for treating IgG4-related disease (IgG4-RD). IgG4 ...

Paris: Sanofi has announced that the European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible ...

A new study published in the Journal of American Medical Association found that Rilzabrutinib decreased itching and hives ...

Rilzabrutinib was added to Sanofi’s pipeline with the acquisition of Principia Biopharma. The candidate is also being developed in mid-stage studies for other immune-mediated diseases like ...

Rilzabrutinib is currently under regulatory review in the US and the EU, with a US Food and Drug Administration target action date of August 29, 2025. Dietmar Berger, MD, PhD ...

Rilzabrutinib is an oral, small molecule, reversible covalent inhibitor of Bruton’s tyrosine kinase (BTK) that modulates immune-mediated processes in ITP.

Rilzabrutinib is an oral, reversible covalent, Bruton’s tyrosine kinase (BTK) inhibitor being investigated for the treatment of immune mediated diseases.

SAN DIEGO — Patients with moderate to severe asthma who were treated with rilzabrutinib showed a reduction in loss of asthma control events, according to a study presented at the American ...

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing ...